Print

Click here to view Assets and Liabilities Statement for the period ended March 31, 2011

Orchid Chemicals & Pharmaceuticals Ltd.
Audited Financial Results for the year ended March 31, 2011
(Rs. Lakhs)
S.No
Particulars
Audited
Stand alone
Consolidated
31-Mar-11
31-Mar-10
31-Mar-11
31-Mar-10
1
 Net Sales / Income from Operations
159467.88

120518.59
171698.61
129872.31
2
 Other Operating Income
7359.63
4585.61
6858.65
4473.02
3
Total Operating Income (1+2)
166827.51
125104.20
178557.26
134345.33
4
 Expenditure        

a) Decrease/(Increase) in Stock in trade
(11964.59)
26945.14
(12506.19)
27303.80
b) Material Cost
86798.76
47207.23
94240.30
53276.96
c) Purchase of Traded Goods
3961.66
3373.83
5155.15
3373.83
 
d) Employees Cost
14138.46
15929.17
16473.24
17448.09
 
e) Depreciation / Amortisation
12845.43
15110.40
13350.40
15489.96
 
f) Other Expenditure
32552.72
48763.98
33210.46
48596.45
g) Total
138332.44
157329.75
149923.36
165489.09
5
Profit from Operations before other Income, Interest & Exceptional Item (3 - 4)
28495.07
(32225.55)
28633.90
(31143.76)
6
Other Income
267.10
7.41
2.99
7.41
7
Profit/(loss) before Interest & Exceptional Item (5+6)
28762.17
(32218.14)
28636.89
(31136.35)
8
 Interest & Finance Charges
11576.50
24123.31
11675.20
24227.03
9
Profit/(loss) after interest but before Exceptional Item (7-8)
17185.67
(56341.45)
16961.69
(55363.38)
10
Exceptional Item - gain/(loss)
194.82
816.55
194.82
816.55
11

Profit/ (Loss) before Tax (9+10)
17380.49
(55524.90)
17156.51
(54546.83)
12
Tax expenses
        
     - Current Tax & Deferred Tax
1432.13
- 
1537.79
- 
13
 Net Profit/ (Loss) after Tax (11-12)
15948.36
(55524.90)
15618.72
(54546.83)
14
Extraordinary Item (net of tax of Rs.12871.42 lakhs)
- 
88658.86
- 
88472.21
15
Net Profit/(Loss) for the period / year
15948.36
33133.96
15618.72
33925.38
16
Paid- up Equity Share Capital (Face value of Rs. 10 each)
7044.21
7044.21
7044.21
7044.21
17
Reserves excluding Revaluation Reserves
106358.27
90919.30
99880.21
86721.74
18
Earnings per share(EPS) before extraordinary item
        
 
   - Basic Rs.
22.64
(78.82)
22.17
(95.97)
 
   - Diluted Rs.
18.71
(78.82)
18.32
(95.97)
19
Earnings per share(EPS) after extraordinary item
        
 
   - Basic Rs.
22.64
47.04
22.17
48.16
 
   - Diluted Rs.
18.71
37.31
18.32
38.21
20
Aggregate of Public Shareholding
     - Number of equity shares
48939460
52128460
48939460
52128460
     - Percentage of Shareholding
69.47
74.00
69.47
74.00
21
Promoters and Promoter group shareholding
a. Pledged / Encumbered
- Number of shares
17181383
15123760
17181383
15123760
 
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)
79.90
82.58
79.90
82.58
 
- Percentage of shares (as a % of the total share capital of company)
24.39
21.47
24.39
21.47
 
b. Non - Encumbered
 
- Numbers of shares
4321233
3189856
4321233
3189856
 
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)
20.10
17.42
20.10
17.42
 
- Percentage of shares (as a % of the total share capital of company)
6.14
4.53
6.14
4.53
 
  1. The above audited financial results were approved by the Board of Directors at its meeting held on Wednesday, May 18, 2011.
  2. The Company is operating in single segment (i.e) "Pharmaceuticals".
  3. The Company has exercised the option provided under the Companies (Accounting Standards) Amendment Rules, 2006 dated 31st March, 2009 in respect of AS 11. The amount remaining to be amortized in the financial statements as on March 31, 2011 on account of exercising the above option is nil (previous period Rs. 1159.22 lakhs).
  4. Exceptional items include exchange gain / (loss) on FCCBs.
  5. The Board has recommended a dividend of Rs.3/- per share on the equity share of Rs.10/- each.
  6. The Company received 15 complaints during the quarter ended March 31, 2011 from the shareholders and no complaints were pending as on March 31, 2011.
  7. Previous year figures have been regrouped wherever necessary.

Place : Chennai
Date : May 18, 2011

For and on behalf of the Board

K. Raghavendra Rao
Chairman & Managing Director